POMDOCTOR VP Dexiang Wei resigns from role

POMDOCTOR LIMITED reported that Dexiang Wei resigned as Vice President, with the resignation dated March 31, 2026 and effective April 1, 2026.

Rhea-AI Filing Summary

POMDOCTOR LIMITED reported that Dexiang Wei resigned as Vice President, with the resignation dated March 31, 2026 and effective April 1, 2026. The company states that his departure was not due to any disagreement with the Board on operations, policies, or practices, and there are no related matters requiring shareholder attention.

Key Figures

Resignation date: March 31, 2026 Effective resignation date: April 1, 2026 Filing month: April 2026 +1 more

4 metrics

Resignation date March 31, 2026 Date Vice President Dexiang Wei resigned

Effective resignation date April 1, 2026 Date resignation became effective

Filing month April 2026 Form 6-K reporting period month

Commission file number 001-42749 SEC registration reference for POMDOCTOR LIMITED

Key Terms

Form 6-K, Report of Foreign Private Issuer, Form 20-F, Securities Exchange Act of 1934

4 terms

Form 6-K regulatory

"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Report of Foreign Private Issuer regulatory

"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover of Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

Securities Exchange Act of 1934 regulatory

"Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did POM (POMDOCTOR LIMITED) disclose in this 6-K?

POMDOCTOR LIMITED disclosed that Vice President Dexiang Wei resigned. His resignation was dated March 31, 2026 and became effective on April 1, 2026. The company indicated the departure was amicable and unrelated to disagreements over operations, policies, or practices.

Did POMDOCTOR LIMITED report any disagreement linked to Dexiang Wei’s resignation?

The company stated that Dexiang Wei’s resignation did not result from any disagreement with the Board of Directors. It specifically mentioned there were no disputes regarding the company’s operations, policies, or practices connected to his departure from the Vice President role.

When did POM’s vice president resignation become effective?

POMDOCTOR LIMITED reported that Vice President Dexiang Wei’s resignation became effective on April 1, 2026. The resignation itself was dated March 31, 2026, creating a one-day gap between the resignation date and the effective date of his departure from the company.

Are there any issues related to the resignation that POM shareholders must consider?

The company explicitly stated there are no matters related to Dexiang Wei’s resignation that need to be brought to shareholders’ attention. This indicates POMDOCTOR LIMITED does not associate the departure with governance disputes or other reportable shareholder concerns.

Who signed the POMDOCTOR LIMITED Form 6-K reporting the resignation?

The Form 6-K was signed by Zhenyang Shi, who serves as POMDOCTOR LIMITED’s Chairman and Chief Executive Officer. His signature confirms the company’s authorization and acknowledgment of the information disclosed regarding the vice president’s resignation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/08/2026 - 09:27 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of April 2026

Commission file number: 001-42749

POMDOCTOR LIMITED

Yongxu Industrial Park
No.19-23 Hejing Road, Dongsha Street
Liwan District, Guangzhou 510000

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Resignation of vice president

On March 31, 2026, Dexiang Wei resigned as Vice President of POMDOCTOR LIMITED (the “Company”), effective as of April 1, 2026. Mr. Wei’s resignation did not result from a disagreement with the Company’s Board of Directors on any matter relating to the Company’s operations, policies or practices. There are no matters relating to such resignation that need to be brought to the attention of the shareholders of the Company.

 1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

POMDOCTOR LIMITED

/s/ Zhenyang Shi

Zhenyang Shi

Chairman and Chief Executive Officer

Date: April 8, 2026

 2